What is the prevalence of Dravet Syndrome?

Dravet Syndrome is a rare, severe form of genetic epilepsy with an estimated prevalence ranging from 1 in 15,700 to 1 in 40,900 individuals. While incidence rates are estimated at approximately 1 in 15,000 to 1 in 20,000 live births, these figures are likely conservative due to historical challenges in clinical recognition and genetic testing.

Is Dravet Syndrome considered rare or ultra-rare?

Dravet Syndrome is classified as a rare disease. Because it is a complex, life-long condition, the prevalence of Dravet Syndrome is often discussed in terms of both pediatric and adult populations. While it is most frequently diagnosed in infancy, individuals with Dravet Syndrome are now living into adulthood, which has shifted how researchers view the total patient population. At DiseaseMaps.org, we have seen a growing cohort of 453 people with Dravet Syndrome who share their lived experiences, providing vital real-world data that complements clinical research registries.

What are the challenges in determining accurate prevalence?

Accurately measuring how many people have Dravet Syndrome is difficult for several reasons. In the past, many patients were misdiagnosed with other forms of epilepsy or developmental delay before the discovery of the SCN1A gene mutation. Because Dravet Syndrome can present with varying degrees of severity, some milder cases may remain undiagnosed or misclassified. Furthermore, the reliance on genetic confirmation means that in regions with limited access to advanced molecular testing, the official incidence statistics may under-represent the true number of affected individuals.

Does Dravet Syndrome affect specific demographics differently?

Current clinical data suggests the following patterns regarding the distribution of Dravet Syndrome:

• Gender Distribution: There is no significant consensus that Dravet Syndrome affects males or females at different rates; both genders are equally susceptible to the SCN1A genetic mutations that cause the condition.


• Age of Onset: This is primarily a pediatric-onset condition, with the first seizure typically occurring within the first year of life, often triggered by fever.


• Geographic/Ethnic Variation: There is no evidence of specific ethnic or geographic clustering for Dravet Syndrome; it appears to occur globally across all populations.

Why is early diagnosis critical for patients?

Because Dravet Syndrome involves a high risk of status epilepticus and requires the avoidance of certain common anti-seizure medications (which can worsen seizures), early identification is essential. The global medical community is working to improve diagnostic speed through expanded newborn screening and increased awareness among pediatric neurologists. As we track the experiences of the 453 members in our DiseaseMaps community, we observe that early intervention and access to specialized care significantly impact the quality of life for families navigating this diagnosis.

Next steps

• Consult a board-certified pediatric neurologist or epileptologist to discuss genetic testing if you suspect a diagnosis.


• Connect with the 453 members on DiseaseMaps.org to share experiences and find emotional support within the community.


• Review resources from the Dravet Syndrome Foundation to stay updated on emerging therapies and clinical trials.


• Keep a detailed seizure diary to assist your medical team in identifying specific triggers.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Dravet Syndrome (ORPHA: 33068)


• NIH Genetic and Rare Diseases Information Center (GARD): Dravet Syndrome


• OMIM (Online Mendelian Inheritance in Man): Epilepsy, Dravet Syndrome (#607208)


• Dravet Syndrome Foundation: Clinical Guidelines and Patient Data